A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy

被引：0
|
作者：
Zandberg, D. P. [1 ]
Chen, J. [2 ]
Tatsuoka, C. [2 ]
Normolle, D. P. [3 ]
Ohr, J. [2 ]
Isett, B.
Rahman, Z. [2 ,5 ]
Fenton, M. [6 ]
Gooding, W. [7 ]
Vujanovic, L. [4 ]
Bao, R. [8 ]
Marsh, C. [2 ]
Seastone, D. [2 ]
Gorantla, V. [1 ]
Pabla, S. [9 ]
Conroy, J.
Ferris, R. L. [5 ]
机构：
[1] Univ Pittsburgh, Div Hematol & Oncol, Dept Med, Med Ctr, Pittsburgh, PA USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] UPMC, Pittsburgh, PA USA
[7] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA USA
[8] UPMC, Div Hematol Oncol, Hillman Canc Ctr, Pittsburgh, PA USA
[9] Labcorp Oncol, Buffalo, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：E4 / E4
页数：1
相关论文
共 50 条
  • [21] Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Borel, Christian
    Jung, Alain C.
    Burgy, Mickael
    CANCERS, 2020, 12 (09) : 1 - 19
  • [22] A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial
    Williamson, S. K.
    Moon, J.
    Huang, C. H.
    Guaglianone, P.
    Wolf, G. T.
    Urba, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC)
    Bonomi, M.
    Klamer, B.
    Bhateja, P.
    Abu-Sbeih, H.
    Rind, F.
    Baliga, S.
    Konieczkowski, D.
    Gogineni, E.
    Dibs, K.
    Faieta, A.
    Grecula, J.
    Old, M.
    Carrau, R.
    Rocco, J.
    Blakaj, D.
    Issa, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S586 - S586
  • [25] Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Alkhatib, Hosam H.
    Maroun, Christopher A.
    Guller, Meytal
    Cooper, Dylan J.
    Wu, Evan S.
    Eisele, David W.
    Fakhry, Carole
    Pardoll, Drew
    Seiwert, Tanguy Y.
    Zhu, Gangcai
    Mandal, Rajarsi
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2024, 170 (03) : 828 - 836
  • [26] A phase II study of ispinesib in patients (PTS) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC)
    Tang, Patricia
    Siu, Lillian L.
    Chen, Eric X.
    Hotte, Sebastien J.
    Chia, Stephen
    Schwarz, James K.
    Colevas, A. Dimitrios
    Johnson, Caitlin
    Pond, Greg R.
    Winquist, Eric
    ANNALS OF ONCOLOGY, 2006, 17 : 186 - 186
  • [27] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [28] ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
    Fayette, J.
    Saada, E. B.
    DeMontfort, A.
    Karabajakian, A.
    Neidhardt, E. M.
    Borel, C.
    Burgy, M.
    Carinato, H.
    Delord, J-P.
    Betrian, S.
    Toussaint, P.
    Chatellier, T.
    Iharidon, T.
    Garin, G.
    Bernardin, M.
    Jaouen, L.
    Sondarjee, I.
    Perol, D.
    Blay, J-Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S851 - S852
  • [29] Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
    Elser, Christine
    Siu, Lillian L.
    Winquist, Eric
    Agulnik, Mark
    Pond, Gregory R.
    Chin, Soo F.
    Francis, Peggy
    Cheiken, Robin
    Elting, James
    McNabola, Angela
    Wilkie, Dean
    Petrenciuc, Oana
    Chen, Eric X.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) : 3766 - 3773
  • [30] Atypical new metastatic sites after immunotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M H&NSCC)
    Deeken, John F.
    Ahmadi, Mahsa
    Johnston, Laura
    Heyer, David M.
    Lee, Patty
    Niknia, Katherine
    Bajaj, Gopal Krishna
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345